The first 60 days: Single-system Langerhans cell histiocytosis (bone, skin or one other organ)
Single-system Langerhans cell histiocytosis is the milder form of this rare histiocytosis, in which the abnormal immune cells affect only one organ, usually a bone or the skin, in a child or young adult. Single bone lesions often heal after biopsy or curettage, skin disease may fade by itself, and gentle vinblastine and prednisone is kept for multiple bone lesions or lesions near the brain. Below, week by week, is what OnCo's record of Single-system Langerhans cell histiocytosis (bone, skin or one other organ) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Biopsy with immunohistochemistry and BRAF testing; skeletal survey or whole-body imaging, blood count, liver tests and abdominal ultrasound to exclude multisystem disease.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis and staging, Unifocal bone disease, Skin-only disease.
- RadiologistNamed in the standard of care for: Diagnosis and staging.
- SurgeonNamed in the standard of care for: Unifocal bone disease, Skin-only disease.
- Medical oncologistNamed in the standard of care for: Multifocal bone or special-site disease, Skin-only disease, Adult single-system or refractory disease.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Biopsy with curettage, with or without intralesional methylprednisolone; observation of healing; indomethacin for pain.
- 2.Multifocal bone or special-site diseaseHistiocyte Society evaluation and treatment guidelines; NCI PDQ
Vinblastine and prednisone for twelve months (LCH-III schedule) to reduce reactivation and central nervous system risk.
Observation or topical corticosteroids; systemic therapy only for extensive symptomatic disease; regular review for progression to multisystem disease.
- 4.Adult single-system or refractory diseaseHistiocyte Society evaluation and treatment guidelines; NCI PDQ
Cytarabine or cladribine; smoking cessation for pulmonary disease; BRAF or MEK inhibitors (vemurafenib, dabrafenib-trametinib, cobimetinib) for refractory disease.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example CD1a and langerinpositive histiocytes on biopsy, BRAF V600E in tissueand cell-free DNA, MAP2K1 and other MAPK alterations, Skeletal survey or whole-body MRI or PET for occult lesions, Pituitary MRI and water balance for special-site disease), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Unifocal bone Langerhans cell histiocytosis, Multifocal bone Langerhans cell histiocytosis, Special-site Langerhans cell histiocytosis.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis and staging
- For my situation (diagnosis and staging), which of the standard options do you recommend and why?Guideline options include: Biopsy with immunohistochemistry and BRAF testing; skeletal survey or whole-body imaging, blood count, liver tests and abdominal ultrasound to exclude multisystem disease.
Unifocal bone disease
- For my situation (unifocal bone disease), which of the standard options do you recommend and why?Guideline options include: Biopsy with curettage, with or without intralesional methylprednisolone; observation of healing; indomethacin for pain.
Multifocal bone or special-site disease
- For my situation (multifocal bone or special-site disease), which of the standard options do you recommend and why?Guideline options include: Vinblastine and prednisone for twelve months (LCH-III schedule) to reduce reactivation and central nervous system risk.
- Am I a candidate for Vinblastine, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of LCH-III apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Skin-only disease
- For my situation (skin-only disease), which of the standard options do you recommend and why?Guideline options include: Observation or topical corticosteroids; systemic therapy only for extensive symptomatic disease; regular review for progression to multisystem disease.
Adult single-system or refractory disease
- For my situation (adult single-system or refractory disease), which of the standard options do you recommend and why?Guideline options include: Cytarabine or cladribine; smoking cessation for pulmonary disease; BRAF or MEK inhibitors (vemurafenib, dabrafenib-trametinib, cobimetinib) for refractory disease.
- Am I a candidate for Cladribine, Vemurafenib, Dabrafenib + trametinib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Dabrafenib + trametinib, Vemurafenib, Cobimetinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Which infants with skin-only disease will progress cannot be predicted”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Whether treating special-site lesions truly prevents neurodegeneration is inferred rather than proven”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Single-system Langerhans cell histiocytosis (bone, skin or one other organ): the full pageSingle-system Langerhans cell histiocytosis is the milder form of this rare histiocytosis, in which the abnormal immune cells affect only one organ, usually a bone or the skin, in a child or young adult. Single bone lesions often heal after biopsy or curettage, skin disease may fade by itself, and gentle vinblastine and prednisone is kept for multiple bone lesions or lesions near the brain.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- BRAF V600E mutation: A single spelling change in the BRAF gene that jams a growth switch permanently on.
- Late effects and survivorship toxicity: Health problems appearing months or decades after treatment ends: heart damage, infertility, second cancers, lymphoedema, dry mouth, memory problems, weak bones.
Every term links to the glossary.